GenoKey

Aalborg, Denmark

GenoKey was founded by Dr Gert Lykke Møller (now Chief Analytics Officer of PrecisionLife), Hans-Christian Brahe Møller and two colleagues. GenoKey pioneered the underlying mathematical approach that enables deep combinatorial analysis of genomic and other clinical and epidemiological patient data. Gert was the first to reduce this innovative approach to computational practice, and this has been developed in collaboration with PrecisionLife into a powerful analytical platform that enables the largest and most detailed precision medicine studies.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out GenoKey on @MedStartr Today #GeneticDisorders #Epidemiology #AllTherapeuticAreas #BigData #ClinicalDataManagement #MedMo #MedStartrVentures

https://www.medstartr.ai/s/NcXFcP6kAmg

Get Involved in GenoKey

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2010
Website: www.genokey.com

Disease Areas

Genetic Disorders Epidemiology All Therapeutic Areas

Technologies

GenomicsData AnalysisBig Data AnalyticsComputational Biology

🌐Website

What do you think of GenoKey?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.